{"generic":"Hydrochlorothiazide","drugs":["Aquazide H","Hydrochlorothiazide","Hydrocot","Microzide","Zide"],"mono":{"0":{"id":"291280-s-0","title":"Generic Names","mono":"Hydrochlorothiazide"},"1":{"id":"291280-s-1","title":"Dosing and Indications","sub":[{"id":"291280-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Edema; Adjunct:<\/b> 25 to 100 mg ORALLY daily in single or divided doses<\/li><li><b>Hypertension:<\/b> initial, 25 mg ORALLY once daily; may increase to 50 mg ORALLY daily in single or 2 divided doses<\/li><\/ul>"},{"id":"291280-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Edema; Adjunct:<\/b> 1 to 2 mg\/kg ORALLY daily in single or 2 divided doses; infants younger than 6 months may require doses up to 3 mg\/kg ORALLY daily in 2 divided doses<\/li><li><b>Edema; Adjunct:<\/b> infants up to 2 years old: MAX dose, not to exceed 37.5 mg ORALLY daily<\/li><li><b>Edema; Adjunct:<\/b> children 2 to 12 years old: MAX dose, not to exceed 100 mg ORALLY daily<\/li><li><b>Hypertension:<\/b> 1 to 2 mg\/kg ORALLY daily in single or 2 divided doses; infants younger than 6 months may require doses up to 3 mg\/kg ORALLY daily in 2 divided doses<\/li><li><b>Hypertension:<\/b> infants up to 2 years old: MAX dose not to exceed 37.5 mg ORALLY daily<\/li><li><b>Hypertension:<\/b> children 2 to 12 years old: MAX dose not to exceed 100 mg ORALLY daily<\/li><li><b>Nocturnal enuresis:<\/b> 25 mg ORALLY once daily approximately 10 hours prior to bedtime (study dosing)<\/li><\/ul>"},{"id":"291280-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment, mild to moderate:<\/b> No adjustment necessary<\/li><li><b>renal impairment, serum creatinine or level greater than 2.5 mg\/dL:<\/b> Do not use<\/li><li><b>renal impairment, progressive renal failure evident by increasing nonprotein nitrogen, increasing blood urea nitrogen, and increasing serum creatinine:<\/b> Discontinue use<\/li><li><b>hepatic impairment:<\/b> No adjustment necessary<\/li><li><b>geriatric:<\/b> Initial doses, 12.5 to 25 mg, with slower titration compared with younger patients<\/li><\/ul>"},{"id":"291280-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Edema; Adjunct<\/li><li>Hypertension<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Bronchopulmonary dysplasia of newborn; Adjunct<\/li><li>Hypercalciuria<\/li><li>Nocturnal enuresis<\/li><li>Osteoporosis<\/li><\/ul>"}]},"3":{"id":"291280-s-3","title":"Contraindications\/Warnings","sub":[{"id":"291280-s-3-9","title":"Contraindications","mono":"<ul><li>anuria<\/li><li>hypersensitivity to hydrochlorothiazide or sulfonamides<\/li><\/ul>"},{"id":"291280-s-3-10","title":"Precautions","mono":"<ul><li>Endocrine and Metabolic:<\/li><li>-- prolonged therapy may cause hypokalemia<\/li><li>-- hyperuricemia or acute gout may be precipitated<\/li><li>-- use caution in patients with parathyroid disease; pathological changes in the parathyroid glands, with hypercalcemia and hypophosphatemia, have occurred with prolonged therapy<\/li><li>-- dilutional and life-threatening hyponatremia may occur in hot weather in edematous patients<\/li><li>-- fluid or electrolyte imbalances such as hyponatremia, hypochloremic alkalosis, hypokalemia, and hypomagnesemia may occur; monitoring recommended<\/li><li>-- use caution in diabetics as hyperglycemia may occur requiring altered insulin dose<\/li><li>-- latent diabetes may be precipitated<\/li><li>Hepatic:<\/li><li>-- severe liver disease; hepatic coma may occur<\/li><li>-- brisk diuresis when severe liver cirrhosis is present may cause hypokalemia<\/li><li>Ophthalmic:<\/li><li>-- angle-closure glaucoma and acute transient myopia may occur within hours to weeks of drug initiation and may lead to permanent vision loss, especially in patients with history of sulfonamide or penicillin allergy; immediate discontinuation recommended<\/li><li>Renal:<\/li><li>-- impaired renal function increases risk of toxicity or azotemia<\/li><li>Concomitant use:<\/li><li>-- corticosteroid or adrenocorticotropin hormone use; hypokalemia may develop<\/li><li>-- lithium use not recommended<\/li><\/ul>"},{"id":"291280-s-3-11","title":"Pregnancy Category","mono":"<ul><li>B (FDA)<\/li><li>C (AUS)<\/li><\/ul>"},{"id":"291280-s-3-12","title":"Breast Feeding","mono":"<ul><li>AAP: Maternal medication usually compatible with breastfeeding.<\/li><li>WHO: Avoid breastfeeding.<\/li><li>Micromedex: Milk effects are possible.<\/li><\/ul>"}]},"4":{"id":"291280-s-4","title":"Drug Interactions","sub":[{"id":"291280-s-4-13","title":"Contraindicated","mono":"<ul>Dofetilide (probable)<\/ul>"},{"id":"291280-s-4-14","title":"Major","mono":"<ul><li>Acetyldigoxin (established)<\/li><li>Arsenic Trioxide (theoretical)<\/li><li>Cyclophosphamide (probable)<\/li><li>Deslanoside (established)<\/li><li>Digitalis (established)<\/li><li>Digitoxin (established)<\/li><li>Digoxin (established)<\/li><li>Droperidol (theoretical)<\/li><li>Flecainide (theoretical)<\/li><li>Ketanserin (theoretical)<\/li><li>Levomethadyl (theoretical)<\/li><li>Lithium (probable)<\/li><li>Methotrexate (probable)<\/li><li>Metildigoxin (established)<\/li><li>Ouabain (theoretical)<\/li><li>Proscillaridin (theoretical)<\/li><li>Sotalol (probable)<\/li><\/ul>"},{"id":"291280-s-4-15","title":"Moderate","mono":"<ul><li>Aceclofenac (probable)<\/li><li>Acemetacin (probable)<\/li><li>Alacepril (probable)<\/li><li>Amtolmetin Guacil (probable)<\/li><li>Aspirin (probable)<\/li><li>Benazepril (probable)<\/li><li>Bepridil (probable)<\/li><li>Bromfenac (probable)<\/li><li>Bufexamac (probable)<\/li><li>Captopril (probable)<\/li><li>Carbamazepine (probable)<\/li><li>Celecoxib (probable)<\/li><li>Cholestyramine (probable)<\/li><li>Choline Salicylate (probable)<\/li><li>Cilazapril (probable)<\/li><li>Clonixin (probable)<\/li><li>Delapril (probable)<\/li><li>Dexibuprofen (probable)<\/li><li>Dexketoprofen (probable)<\/li><li>Diclofenac (probable)<\/li><li>Diflunisal (probable)<\/li><li>Dipyrone (probable)<\/li><li>Enalapril (probable)<\/li><li>Enalaprilat (probable)<\/li><li>Etodolac (probable)<\/li><li>Etofenamate (probable)<\/li><li>Etoricoxib (probable)<\/li><li>Felbinac (probable)<\/li><li>Fenoprofen (probable)<\/li><li>Fepradinol (probable)<\/li><li>Feprazone (probable)<\/li><li>Floctafenine (probable)<\/li><li>Flufenamic Acid (probable)<\/li><li>Flurbiprofen (probable)<\/li><li>Fosinopril (probable)<\/li><li>Ginkgo (probable)<\/li><li>Gossypol (probable)<\/li><li>Ibuprofen (probable)<\/li><li>Ibuprofen Lysine (probable)<\/li><li>Imidapril (probable)<\/li><li>Indomethacin (probable)<\/li><li>Ketoprofen (probable)<\/li><li>Ketorolac (probable)<\/li><li>Licorice (probable)<\/li><li>Lisinopril (probable)<\/li><li>Lornoxicam (probable)<\/li><li>Loxoprofen (probable)<\/li><li>Lumiracoxib (probable)<\/li><li>Meclofenamate (probable)<\/li><li>Mefenamic Acid (probable)<\/li><li>Meloxicam (probable)<\/li><li>Moexipril (probable)<\/li><li>Morniflumate (probable)<\/li><li>Nabumetone (probable)<\/li><li>Naproxen (probable)<\/li><li>Nepafenac (probable)<\/li><li>Niflumic Acid (probable)<\/li><li>Nimesulide (probable)<\/li><li>Oxaprozin (probable)<\/li><li>Oxyphenbutazone (probable)<\/li><li>Parecoxib (probable)<\/li><li>Pentopril (probable)<\/li><li>Perindopril (probable)<\/li><li>Phenylbutazone (probable)<\/li><li>Piketoprofen (probable)<\/li><li>Piroxicam (probable)<\/li><li>Proglumetacin (probable)<\/li><li>Propionic Acid (probable)<\/li><li>Propyphenazone (probable)<\/li><li>Proquazone (probable)<\/li><li>Quinapril (probable)<\/li><li>Ramipril (probable)<\/li><li>Rofecoxib (probable)<\/li><li>Salicylic Acid (probable)<\/li><li>Salsalate (probable)<\/li><li>Sodium Salicylate (probable)<\/li><li>Spirapril (probable)<\/li><li>Sulindac (probable)<\/li><li>Temocapril (probable)<\/li><li>Tenoxicam (probable)<\/li><li>Tiaprofenic Acid (probable)<\/li><li>Tolfenamic Acid (probable)<\/li><li>Tolmetin (probable)<\/li><li>Topiramate (probable)<\/li><li>Trandolapril (probable)<\/li><li>Valdecoxib (probable)<\/li><li>Zofenopril (probable)<\/li><\/ul>"}]},"5":{"id":"291280-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Hypotension<\/li><li><b>Dermatologic:<\/b>Phototoxicity<\/li><li><b>Neurologic:<\/b>Vertigo<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Cardiac dysrhythmia<\/li><li><b>Dermatologic:<\/b>Stevens-Johnson syndrome, Toxic epidermal necrolysis<\/li><li><b>Endocrine metabolic:<\/b>Dilutional hyponatremia, Hypercalcemia, Hyperglycemia, Hypokalemia, Hypomagnesemia, Hyponatremia, Hypophosphatemia<\/li><li><b>Gastrointestinal:<\/b>Cholecystitis, Pancreatitis<\/li><li><b>Hepatic:<\/b>Cholestatic jaundice syndrome<\/li><li><b>Ophthalmic:<\/b>Angle-closure glaucoma, acute, Myopia, Acute transient<\/li><li><b>Renal:<\/b>Renal failure, Renal impairment<\/li><\/ul>"},"6":{"id":"291280-s-6","title":"Drug Name Info","sub":{"0":{"id":"291280-s-6-17","title":"US Trade Names","mono":"<ul><li>Aquazide H<\/li><li>Hydrocot<\/li><li>Microzide<\/li><li>Zide<\/li><\/ul>"},"2":{"id":"291280-s-6-19","title":"Class","mono":"<ul><li>Cardiovascular Agent<\/li><li>Diuretic<\/li><li>Thiazide<\/li><\/ul>"},"3":{"id":"291280-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"291280-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"291280-s-7","title":"Mechanism Of Action","mono":" Hydrochlorothiazide is an antihypertensive and diuretic agent that affects the electrolyte reabsorption at the distal renal tubule resulting in increased excretion of sodium and chloride in equal amounts. The antihypertensive action of thiazides is still unknown.<br\/>"},"8":{"id":"291280-s-8","title":"Pharmacokinetics","sub":{"2":{"id":"291280-s-8-25","title":"Metabolism","mono":"Not metabolized <br\/>"},"3":{"id":"291280-s-8-26","title":"Excretion","mono":"Renal: at least 61% unchanged <br\/>"},"4":{"id":"291280-s-8-27","title":"Elimination Half Life","mono":"5.6 h to 14.8 h <br\/>"}}},"10":{"id":"291280-s-10","title":"Monitoring","mono":"<ul><li>blood pressure, urine output, reduction in edema<\/li><li>serum and urine electrolytes (eg; potassium, sodium, calcium, magnesium)<\/li><li>renal function, hepatic function, CBC<\/li><li>serum uric acid, blood glucose<\/li><\/ul>"},"11":{"id":"291280-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/><ul><li>Oral Capsule: 12.5 MG<\/li><li>Oral Tablet: 12.5 MG, 25 MG, 50 MG<\/li><\/ul><\/li><li><b>Hydrocot<\/b><br\/>Oral Tablet: 25 MG, 50 MG<br\/><\/li><li><b>Microzide<\/b><br\/>Oral Capsule: 12.5 MG<br\/><\/li><\/ul>"},"12":{"id":"291280-s-12","title":"Toxicology","sub":[{"id":"291280-s-12-31","title":"Clinical Effects","mono":"<b>DIURETICS<\/b><br\/>USES: Class of drugs that are primarily used to treat hypertension and congestive heart failure. Potassium sparing diuretics and carbonic anhydrase inhibitors are covered in separate managements. PHARMACOLOGY: Work in a variety of mechanisms including inhibiting sodium and chloride reabsorption in the distal convoluted tubule (thiazides), inhibiting transport of sodium, potassium, and chloride in the thick ascending limb of the loop of henle (loop), and osmotic agents (mannitol). TOXICOLOGY: Produce hypovolemia and electrolyte deficiencies. EPIDEMIOLOGY: Rare overdose which uncommonly results in significant morbidity or death. MILD TO MODERATE TOXICITY: Mild dehydration, tachycardia, dry mucous membranes, headache, muscle cramps, thirst, and brisk diuresis. Large doses of furosemide or ethacrynic acid can cause ototoxicity. SEVERE TOXICITY: Hypotension, hypochloremic metabolic alkalosis, mental status changes, and electrolyte abnormalities (i.e. hypokalemia, hypomagnesemia, hypochloremia, hypocalcemia) are the most common manifestations of severe poisoning. Rarely muscle spasms, tetany, seizures, coma, or dysrhythmias may develop secondary to severe electrolyte abnormalities.  CNS depression has been reported rarely in children with acute ingestion without significant electrolyte abnormalities. ADVERSE EFFECTS: Thiazides are associated with hyperglycemia and hyperlipidemia. Furosemide has been associated with ototoxicity, hyperglycemia, and hypercholesterolemia.  Diuretics have a large number of drug interactions as well. Extravasation of mannitol can cause tissue injury and compartment syndrome.<br\/>"},{"id":"291280-s-12-32","title":"Treatment","mono":"<b>DIURETICS<\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: Patients with minor symptoms can be managed with supportive care only.  Oral hydration and oral electrolyte supplementation may be sufficient.  Severe electrolyte disturbances and\/or mental status changes indicate a more severe poisoning. MANAGEMENT OF SEVERE TOXICITY: Severe toxicity is very rare. Treatment should be directed at intravenous correction of volume loss and electrolyte abnormalities.<\/li><li>Decontamination: PREHOSPITAL: Prehospital decontamination is not indicated as toxicity is rare. HOSPITAL: Activated charcoal is rarely  indicated as acute toxicity is rare.<\/li><li>Airway management: Diuretic poisoning should not produce symptoms mandating airway management.<\/li><li>Antidote: There is no specific antidote.<\/li><li>Monitoring of patient: Monitor vital signs and serum electrolytes.  Obtain an ECG in patients with significant electrolyte abnormalities.<\/li><li>Enhanced elimination procedure: Hemodialysis is not expected to be helpful.<\/li><li>Patient disposition: HOME CRITERIA: Asymptomatic patients with inadvertent ingestion of less than a maximal daily dose can be monitored at home. OBSERVATION CRITERIA: Adults with intentional ingestions or symptomatic children should be referred to a health care facility.  Patients who are asymptomatic after 6 hours can be discharged home. ADMISSION CRITERIA: Patients who have severe electrolyte abnormalities or vital sign abnormalities should be admitted. CONSULT CRITERIA: Consult a poison center or medical toxicologist for assistance in managing severe poisonings.<\/li><\/ul>"},{"id":"291280-s-12-33","title":"Range of Toxicity","mono":"<b>DIURETICS<\/b><br\/>TOXICITY: Toxic doses are not well established.  Diuresis is expected to result at even therapeutic doses.  Toxicity is most common with chronic dosing and acute toxicity is often related to other factors such as comorbid conditions and access to fluid replacement. THERAPEUTIC DOSE: Furosemide is typically dosed at 20 to 80 mg with repeat doses as necessary in adults; pediatric dose is 1 to 2 mg\/kg orally.  Hydrochlorothiazide is typically dosed at 12.5 to 50 mg daily in adults; pediatric dose is 1 to 3 mg\/kg divided twice daily.<br\/>"}]},"13":{"id":"291280-s-13","title":"Clinical Teaching","mono":"<ul><li>Warn patient to avoid activities requiring mental alertness or coordination until drug effects are realized, as drug may cause blurred vision, vertigo, or dizziness.<\/li><li>Drug may cause electrolyte imbalances (hyperuricemia, hyponatremia, hypercalcemia), constipation, diarrhea, nausea, vomiting, paresthesias, muscle spasm, photosensitivity, rash, restlessness, or impotence.<\/li><li>Advise patient to report signs\/symptoms of acute transient myopia associated with acute angle-closure glaucoma, including sudden ocular pain or decreased visual acuity.<\/li><li>Counsel diabetic patient to monitor for signs\/symptoms of hyperglycemia and to report difficulties with glycemic control.<\/li><li>Tell patient to maintain adequate hydration, especially with exercise, sweating, diarrhea, or vomiting.<\/li><li>Advise patient to report signs\/symptoms of hypotension, hypokalemia, or hypomagnesemia.<\/li><li>Instruct patient to avoid alcohol while taking drug as orthostatic hypotension may be aggravated.<\/li><li>Warn patient that there are multiple significant drug-drug interactions for this drug and to consult a healthcare professional prior to new drug use (including over-the-counter and herbal drugs).<\/li><\/ul>"}}}